Imiglitazar

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameImiglitazar
Drug Alias Name伊格列扎TAK-559
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonists
TargetsPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A